Three-Year Outcomes of Endovascular Therapy Using Covered Stent-Grafts Versus Interwoven Nitinol Stents in Severely Calcified Femoropopliteal Artery Disease From a Retrospective Multicenter Registry
Purpose: This study aimed to compare the long-term safety and efficacy of Viabahn covered stent-grafts (CSG) and Supera peripheral stents (SPS) in calcified femoropopliteal artery lesions. Materials and Methods: We retrospectively analyzed 341 cases who had Rutherford class 2 to 6 peripheral artery disease and underwent endovascular therapy (EVT) with either CSG (n = 137) or SPS (n = 204) for femoropopliteal lesions with bilateral calcification assessed by fluoroscopic image based on Peripheral Arterial Calcium Scoring System classification, between April 2017 and February 2021 at 7 cardiovascular centers in our country. Results: Following propensity score (PS) matching, the final study population comprised 142 matched patients with no remarkable intergroup difference in baseline characteristics. The 3-year primary patency was 70.9% in the CSG group and 56.2% in the SPS group, respectively, and was not statistically different ( P = .083). Moreover, no significant difference was noted in freedom from target lesion revascularization (72.8% vs 63.5%, P = .16), limb salvage rate (100.0% vs 96.2%, P = .32), and overall survival rate (67.6% vs 66.6%, P = .61). Stratification analysis revealed that advanced age and current smoking had a significant interaction on the association of CSG versus SPS implantation with restenosis (interaction P < .05). Conclusion: In patients with severely calcified femoropopliteal lesions, the 3-year primary patency was not significantly different between EVT using CSG and SPS following PS matching. Clinical Impact Severe calcification in femoropopliteal disease remains a challenge for EVT. Covered stent-graft and SPS are reliable devices for calcified femoropopliteal lesions. We compared the 3-year outcomes in patients undergoing EVT using either CSG or SPS. Following the propensity matching, the 3-year primary patency was not different at 70.0% and 56.2% ( P = .083) in the CSG (n = 71) and SPS (n = 71) groups, respectively. Moreover, no significant difference was noted in freedom from target lesion revascularization and limb salvage rate.
Authors
- Yo Iwata (ORCID: https://orcid.org/0000-0002-6969-4456)
- Shinsuke Mori (ORCID: https://orcid.org/0000-0001-9037-867X)
- Kazuki Tobita (ORCID: https://orcid.org/0000-0002-1913-6894)
- Mitsuyoshi Takahara (ORCID: https://orcid.org/0000-0001-5105-041X)
- Tatsuya Nakama (ORCID: https://orcid.org/0000-0001-9107-6438)
- Akiko Tanaka (ORCID: https://orcid.org/0000-0003-0238-1436)
- Kazunori Horie (ORCID: https://orcid.org/0000-0002-8614-7729)
- Naoki Hayakawa (ORCID: https://orcid.org/0000-0002-4168-2808)
- Kenji Suzuki
Institutions
- Saiseikai Central Hospital (JP)
- Funabashi Municipal Medical Center (JP)
- Asahi General Hospital (JP)
- Shonan Kamakura General Hospital (JP)
- Saiseikai Yokohama Eastern Hospital (JP)
- Sendai Kousei Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Journal of Endovascular Therapy
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1177/15266028261507045
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00